Dr Tara Speranza

05/24/2021

Dr Tara Speranza  brings over two decades of experience spanning scientific research, commercial strategy and capital markets within the healthcare and biotechnology sectors.

Dr Speranza has over a decade of experience in academia, holding senior research positions at the University of Sydney and the University of Geneva, where her research focused on novel molecular targets and translational drug development. During this time, she led a successful commercial partnership with global pharmaceutical company, Servier, resulting in the development and commercialisation of the anti-osteoporotic therapy, Protelos.

Following her academic career, Dr Speranza has held roles across investment, strategic advisory and capital markets, supporting biotechnology and healthcare companies in valuation, capital raising, and strategic positioning. She has been directly involved in assessing and progressing investments and partnerships across a range of early- and late-stage healthcare assets, including licensing and transaction processes.